In the upcoming World Vaccine Congress Asia 2013, listen to Mr. Shunsuke Sami as he covers the topic "Asian Partnership Model for Bioventure: Driving therapeutic vaccine development for unmet medical needs". He will be talking about redefining AnGes' business and partnership strategy and R&D focus to developing innovative therapeutic vaccines and builing a strategic partnership with BioLeaders and Vical to develop therapeutic vaccines addressing medical needs in cancer. Apart from this, Mr. Sami will share about how to leverage on expertise and resources in research partners to fast-track vaccine R&D programmes.
Mr. Shunsuke Sami is currently the Executive Vice President of AnGes MG, Japan. Prior to joining AnGes, he worked in positions including Director of Business Development at Bristol Myers Japan and a bench chemist, later involved in coordination and planning of R&D, licensing and corporate planning, at Sumitomo Pharmaceuticals.
Join us at the World Vaccine Congress Asia 2013 held from the 17th – 20th of June 2013 at Grand Copthorne Waterfront Hotel, Singapore. Don't miss out on this highly anticipated event! Register here to attend now!